With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

This drug is again a once-a-week injection that combines the long-acting amylin analogue, cagrilintide, with semaglutide. It works in a similar way to just semaglutide, but may offer better ...

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...

Novo Nordisk itself, meanwhile, recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – that will ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...

Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss.

In Novo Nordisk’s trial, there were only 1.2 GI adverse events per patient year in the cagrilintide treatment arm, versus 2.6 for semaglutide and 2.8 for CagriSema. Unlike incretin therapies ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...